APN: APAC sale unlocks value, reduces debt, and shifts focus to high-growth pharma and manufacturing

About this update from Aspen Pharmacare Holdings Limited

Divestment of the APAC business for ZAR 26.5 billion will significantly reduce debt and enhance balance sheet flexibility, with proceeds used to drive organic growth in pharma and manufacturing. GLP-1s and contract manufacturing are key future growth drivers.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Aspen Pharmacare Holdings Limited